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ABSTRACT 
Improved methods of bone regeneration are needed in the craniofacial 
rehabilitation of patients with significant bone deficits secondary to tumor 
resection, for congenital deformities, and prior to prosthetic dental reconstruction. 
In this study, a gene enhanced tissue engineering approach was used to assess 
bone regenerative capacity of Sonic hedgehog (Shh) transduced gingival 
fibroblasts, mesenchymal stem cells, and fat derived cells delivered to rabbit 
cranial bone defects in an alginate/collagen matrix. 
RT-PCR analysis demonstrated that the transduced primary rabbit cell 
populations expressed Shh RNA.  Shh protein secretion was confirmed by 
ELISA.  After six weeks, new full-thickness bone was seen emanating directly 
from the alginate/collagen matrix in Shh transduced groups. Quantitative two-
dimensional digital analysis of histological sections confirmed statistically 
significant (p<0.05) amounts of bone regeneration in all three Shh enhanced 
groups compared to controls. Necropsy failed to demonstrate any evidence of 
treatment-related side effects. 
This is the first study to demonstrate that Shh delivery to bone defects, in this 
case through a novel gene enhanced tissue-engineering approach, results in 
significant bone regeneration.  This encourages further development of the Shh 
gene enhanced tissue engineering approach for bone regeneration. 
INTRODUCTION 
Indications for bone grafting in dental and craniofacial reconstruction include 
bone augmentation prior to prosthetic reconstruction, fracture repair, and repair 
of facial bone defects secondary to trauma, tumor resection, and congenital 
deformities.  The ideal graft material provides a source of cells capable of 
forming bone when suitably induced, provides the appropriate signals to induce 
bone formation (an osteoinductive environment), and provides a scaffold for new 
bone formation (an osteoconductive environment). 
Gene-based therapies involve delivering a specific gene to target tissue with the 
goal of changing the phenotype or protein expression profile of the recipient cell. 
Our goal was to employ a gene-enhanced tissue engineering approach to 
develop a bone grafting material that would prove effective at regenerating both 
small and large osseous defects of the craniofacial region. The ultimate goal of 
gene-enhanced tissue engineering is to recapitulate the stages of bone 
regeneration to produce bone that is indistinguishable from normal host bone.  
The regulation of bone metabolism is mediated by both systemic and local 
factors1. Of these, the bone morphogenetic proteins and Sonic hedgehog appear 
to be key regulators involved in the formation of new bone, both embryologically 
and in the repair of fractures. 
 
BMPs are a family of morphogens that regulate bone formation and promote fracture 
healing, in part by stimulating the differentiation of non-committed precursor cells into 
osteoblasts2.  While studies involving the use of exogenously administered recombinant 
BMP-2 and BMP-7 to induce bone regeneration have generally been promising in lower 
animals3,4,5, human studies have demonstrated a large variation in response to 
recombinant BMP6. Additionally, the short in vivo half-life of rBMPs7, coupled with the 
ability of pharmacologic doses of BMPs to stimulate osteoclast production8, may limit 
the usefulness of recombinant BMPs in the clinical setting9. 
 
Sonic hedgehog (Shh), a 45 kD vertebrate homologue of the Drosophila segment 
polarity gene (Hedgehog) and a member of the Hedgehog gene family (Sonic, 
Desert, and Indian Hedgehog), is a key protein involved in craniofacial 
morphogenesis. Shh causes differentiation of pluripotent mesenchymal stem 
cells into osteoblastic lineage by upregulating BMPs via Smad signaling10. Shh 
also induces cell proliferation in a tissue-specific manner during embryogenesis 
via the regulation of epithelial-mesenchymal interactions (e.g. hair follicles11 and 
teeth12,13). 
 
The importance of Shh to craniofacial morphogenesis has been demonstrated in 
experiments with Shh null mutant mice in which the first branchial arch, which 
gives rise to both the mandible and maxilla, fails to form14.  Moreover, mutations 
in the human Shh gene have been shown to cause holoprocencephaly15, a 
developmental field defect in which the cerebral hemispheres fail to separate into 
distinct halves. Associated anomalies include hypotelorism, midline cleft 
lip/palate, proboscis-like nasal structures, and premaxillary agenesis. Mutations 
of the Shh gene have been identified in the rare dental anomaly, solitary median 
maxillary central incisor16. Excess Shh leads to a mediolateral widening of the 
frontonasal process and hypertelorism15. 
 
Shh increases the commitment of pluripotential mesenchymal cells into the 
osteoblastic lineage10,17 by stimulating the expression of a cascade of 
downstream genes involved in bone development18,19,20. Transduction of an Shh-
coding adenovirus into mouse embryo induces the ectopic expression of BMP4, 
Patched-1, Patched-2, and Gli121. Ectopic bone formation can be induced in 
athymic mice by transplantation of Shh-transfected chicken fibroblast cells17. 
Implantation of Shh-enhanced chicken embryo-derived dermal fibroblasts into 
nude mice results in ectopic cartilage and bone formation22. However, 
intramuscular transplantation of Shh protein alone does not induce bone 
formation23. This suggests that either the in vivo half-life of Shh is too short to 
establish the gradient required of Shh to exert it’s effect24, or that Shh must 
function in concert with other downstream factors involved in bone regeneration. 
 
Shh induces the expression of multiple BMPs thus mimicking the complex 
mixture of BMP heterodimers normally present in developing bone. We expected 
that the Shh transduced cells would secrete Shh, resulting in the co-ordinated 
downstream expression of multiple bone growth factors implicated in bone repair 
and regeneration, including the BMPs. Genetic enhancement of cells with Shh 
should result in better bone repair than methods employing direct protein delivery 
or genetic enhancement approaches using individual BMPs. 
 
In this study, the Shh gene from human fetal lung tissue was cloned into the 
replication incompetent retroviral vector expression series LN25. The rat beta-
actin enhancer/promoter was engineered to drive expression of Shh.  In order to 
identify a cell population having the best osteogenic potential, three different 
primary cell populations: gingival fibroblasts, fat-derived stem cells and 
periosteal-derived cells were genetically enhanced with the Shh vector.  Shh 
expression was confirmed in transduced cells at the RNA and protein levels by 
RT-PCR and ELISA.  Cells were introduced into adult (age 6 months, weighing 
2.8 to 3.4kg) male New Zealand White rabbit calvarial defects using a novel 
alginate/type I collagen composite bone graft matrix.  A total of eight groups 
(N=6) were examined: unrestored empty defects, matrix alone, matrix plus the 
three cell populations transduced with both control and Shh expression vectors.  
The bone regenerative capacity of Shh gene enhanced cells was assessed 
grossly, radiographically and histologically at 6 and 12 weeks post-implantation  
 
RESULTS 
Cloning of Human Shh cDNA  
Shh is highly expressed in fetal lung tissue. This tissue was used as the source 
of total RNA for cDNA cloning of Shh by RT-PCR.26   Due to the high GC content 
of the Shh cDNA, it was not possible to isolate an undeleted Shh cDNA as a 
single contiguous fragment.  Instead, the Shh cDNA was assembled using 
conventional molecular biology techniques from five smaller fragments.  In one 
particularly unstable GC rich section of the Shh gene, silent mutations were 
incorporated into the nucleotide sequence to reduce the GC content without 
altering the amino acid sequence (see Table 1).  With this exception, DNA 
sequencing of the entire Shh 5’ untranslated region and coding sequence 
confirmed the reported human Shh sequence.27 
 
Retroviral Vector Plasmid and Particle Generation 
Amphotropic retroviral vector particles harboring LNCX (Neo control vector) and 
LNB-Shh were generated from cloned producer cells lines at high titer.  The β 
actin enhancer/promoter was chosen for driving expression of Shh because it is 
a weaker “housekeeping” enhancer/promoter than the strong viral 
cytomegalovirus (CMV) enhancer/promoter, which often causes toxic 
overexpression of potent cytokines and morphogens28.  Thus we have performed 
limited dosing experiments by testing strong and weak enhancer/promoters to 
drive transgenes in primary mesenchymal stem cells and other cells in vitro. We 
found that the β-actin enhancer/promoter is preferred due to its reasonable 
expression levels with resultant lack of toxicity.  The Moloney murine leukemia 
virus LTR is used to drive expression of the neomycin resistance gene in both 
vectors (Figure 1). 
 
Reverse-Transcriptase- Polymerase Chain Reaction (RT-PCR) Analysis of Shh 
Expression 
Shh RNA expression was confirmed in the 3 transduced cell lines by RT-PCR 
using vector-specific primers. The results (Figure 2) showed that the LNB-Shh 
transduced periosteal cells expressed Shh at the RNA level while control-
transduced cells did not. The gingival fibroblasts and fat-derived cells gave 
similar results. Controls included GAPDH for RNA integrity and reverse 
transcription positive controls; no template as negative control and plasmid DNA 
as the PCR positive control. 
 
Shh Protein Production by Enzyme-Linked Immunosorbent Assay (ELISA) 
Forty-eight hour low serum conditioned media was used in ELISA. Shh 
transduced periosteal stem cells secreted the greatest amount of Shh (Figure 3). 
This is comparable to the level of BMP production previously observed in 
osteochondral defect studies using LNB-BMP-7 transduced periosteal-derived 
cells29. Background levels were minimal in control-transduced cells.  
 
Assembly Of Alginate/Type I Collagen/Cell Composites and Assessment of in 
vitro Viability  
Several different materials and various combinations of materials were assessed 
for use as a matrix prior to selection of the alginate/type I collagen mixture.  
Matrigel (BD Biosciences, Franklin Lakes, NJ), gelatin, agar, Gelfoam (Johnson 
and Johnson, Summerville, NJ), and BioOss (Luitpold Pharmaceuticals, Shirley, 
NY) all gave inferior handling and cell compatibility properties compared to the 
alginate/type I collagen composite material. 
Alginate is a biodegradable polysaccharide composed of mannuronic and 
guluronic acid units.  The porous nature of alginate gels allows for the migration 
of cells and regulatory proteins inside the network30. The alginate used in these 
studies was from Macrocystitis pyrifera (kelp) with a medium viscosity and is 
composed of 61 % mannuronic and 39 % guluronic acid and a molecular weight 
of ~100,000 Daltons.  
Type I collagen (1%) was added to increase the osteoconductive potential of the 
alginate31.To assess the viability of cells in this alginate/type I collagen composite 
bone graft material, composites were prepared and submitted for histological 
sectioning immediately after assembly (time 0) and after 7 days in culture. Cells 
were evenly distributed throughout the graft material at time 0 (Figure 4A).  
Although cells were not cultured in the graft material prior to implant into defects, 
it was necessary to first demonstrate that the graft material was biocompatible.  
After one week in culture, the cells were healthy and had expanded in clusters 
throughout the graft (Figure 4B), demonstrating the suitability of this graft 
material.      
 
Bone Regeneration at 6 and 12 Weeks 
Figure 5 is representative of results at 6 weeks for all cell types.  Empty defects, 
matrix alone, and control transduced cells show minimal levels of bone 
regeneration.  Conversely, Shh transduced cells show very substantial levels of 
bone regeneration radiographically. 
For a more quantitative assessment of bone regeneration, composite 
photomicrographs were assembled from histological sections that were taken 
through the center of the defects. Only a thin layer of fibrous connective tissue 
formed in the unrestored empty defect group (Figure 6A). Matrix alone (without 
cells) integrated into the defects, but again there was only minimal bone 
formation (data not shown).  However, in all matrix-containing groups, the 
thickness of the defect space was effectively preserved. The defects restored 
with control-transduced cells plus matrix demonstrated only minimal bone 
formation (Figure 6B). At higher magnification, control transduced cells within the 
matrix could still be seen after 6 weeks in vivo.  
Conversely, Shh gene-enhancement of the periosteal-derived cells resulted in 
the formation of fine trabeculae of new bone, primarily along the edges of the 
defect (Figure 6C). This new bone was composed of fine trabeculae, and had a 
somewhat delicate appearance. The Shh-enhanced fat-derived stem cells 
appeared to form relatively thick trabeculae of bone, but this new bone was not 
well dispersed throughout the defect (Figure 6D).  Even dispersal of new bone 
was complicated by the observation that the use of fat-derived stem cells often 
resulted in growth of cyst-like structures in both the control transduced and gene-
enhanced groups.  These cyst-like structures were not seen with periosteal 
derived cells or gingival fibroblasts.  
 
The best results were seen with the Shh-transduced gingival fibroblasts, where a 
substantial amount of new bone formation formed throughout the matrix (Figure 
6E). Equally significant was the thickness of this new bone. On high power 
histologic examination, the new bone was shown to be emanating directly from 
the matrix (Figure 7). 
  
Results at 12 weeks (Figure 8A-E, Figure 9A-D) were similar to the findings at 6 
weeks.  Consistent with the 6 week data, the best 12 week results were seen 
with the Shh-enhanced gingival fibroblasts, where near full thickness bone 
formation was seen throughout the defect. At higher magnification, significant 
new bone formation and bone marrow was evident (Figure 10). 
 
Quantitative digital analysis of histological sections was performed and the total 
2-dimensional amount of new bone was determined using Adobe Photoshop. A 
comparison of bone regeneration at 6 weeks versus 12 weeks showed 
statistically significant new bone formation in all three Shh-enhanced cell lines at 
both time points compared to controls (Figure 11). 
 Finally, regarding the safety of stably transducing cells to express Shh in vivo, 
autopsies performed on Shh-transduced rabbits failed to demonstrate any 
evidence of treatment-related side effects after 12 weeks. 
 
DISCUSSION 
 
The adult rabbit calvarial “critical size defect” model was chosen because the 
cranial bones, like the maxilla and mandible, are formed through 
intramembranous ossification32,33. This model has been extensively investigated 
and characterized with regards to its intrinsic bone healing capacity34.  
Based on the early work of Frame34, a critical size calvarial defect (CSD; defined 
as a defect that will not heal completely during the life span of the animal) in the 
adult rabbit was determined to be 15 mm in diameter, when examined 24 weeks 
post surgery. 
However, the concept of CSD is in flux. Because most studies are of limited 
duration and do not extend over the life of the animal, the CSD is now being re-
defined as the size of the defect that does not heal over the length of the study35. 
Previous definitions of CSD were based on a two-dimensional, linear 
measurement of bone formation, and did not take into account the overall 
thickness of the new bone. Consequently, cranial defects that developed a 
continuous, even if very thin, shelf of bone over the surgical site were considered 
healed. However, the most important parameter of success in bone healing is the 
total three-dimensional amount of new bone deposited in the defect, because the 
goal in most craniofacial applications of bone regeneration is to restore the site to 
its original three-dimensional state. Therefore, an 8mm defect size was chosen 
since there is ample evidence36 to suggest that this sized defect does not heal 
spontaneously over a 12-week period.   
Our results clearly demonstrate that minimal bone regeneration occurred in 
empty 8mm defects which validates this size defect for study of bone 
regeneration at time points up to 12 weeks. Regarding control groups, we chose 
to use control transduced cells as the best control group for these studies.  
Control transduced cells were genetically enhanced with the neomycin resistance 
gene and selected in G418.  Shh transduced cells were treated identically as 
control cells with the exception that the vector they were transduced with 
contained the Shh gene driven from the beta actin promoter in addition to the 
neomycin resistance gene.  We chose not to use non-transduced cells as a 
control because in previous experiments in which non-transduced cells were 
used, there was no statistical difference in bone regeneration between the control 
transduced and non-transduced groups37.  Consequently, the control transduced 
cells serve as the most suitable control for these studies. 
 
The matrix is a critical component of any tissue engineering protocol involving 
anchorage-dependent cells. Ideally, the matrix should be easy to handle, allow 
for adherence of cells, and provide a three-dimensional scaffold of sufficient 
strength to hold the defect space.  It must also be porous enough to allow for the 
free diffusion of cells and growth factors. Purified bovine collagen is 
biocompatible, and because it promotes the mineralization process, it is also 
osteoconductive.  However, we found that a collagen-based system alone did not 
afford a matrix with the requisite strength to hold the defect space. Moreover, 
collagen gels tend to contract and lose their shape and consistency after as little 
as 12 hours in culture38.  
Alginate hydrogels are used extensively in cell encapsulation and tissue 
engineering applications39 because of their structural properties and good 
biocompatibility40. The porous nature of alginate gels allows for the migration of 
cells and cytokines inside the network. Bone marrow stromal cells embedded in 
alginate alone have been used to regenerate rabbit osteochondral defects 38and 
sheep cranial defects41, with no evidence of a host immune response. While 
alginate gels alone support cell proliferation, proliferation can be enhanced by the 
addition of an osteoconductive material to the matrix42.  
Our results demonstrate improved bone regeneration through use of a novel 
alginate/type I bovine collagen-based matrix in which the alginate provides a 
structural mesh around the cells and the collagen supplies the desired 
osteoconductive properties to the graft.  
 
Variations in the signaling range of Shh appear to be due to tissue-specific 
differences in intracellular processing and tissue-restricted expression of binding 
proteins. This suggests that the ability of cells to respond to Shh may be 
dependent on the stage of differentiation of the particular cell, with only immature 
pluripotential cells being capable of differentiating into an osteoblastic lineage10. 
Consequently, three cell types originating from different tissues were analyzed: 
gingival fibroblasts, fat-derived stem cells and periosteal-derived cells. All of 
these cell types are in plentiful supply and easily harvested.  Gingival fibroblasts 
can be induced to express an osteoblastic phenotype43,44. Tissue obtained by 
liposuction contains a mesenchymal stem cell-like population (fat-derived stem 
cells) that can be induced to differentiate into bone when placed in an 
appropriate medium45. Periosteal-derived cells were selected because of their 
proven ability to repair bone defects when transfected with BMP-expressing 
retroviral vectors28. 
The selection of the number of cells implanted per defect (2x106 cells) was based 
on the dose-response curves of Gysin et al46, who demonstrated that the 
optimum cell count for an 8 mm calvarial defect was 1-2x106 BMP-expressing 
cells. However, our results suggest that this total cell count may be insufficient for 
complete bone regeneration by 12 weeks. In some areas where new bone 
formation was not complete, the remaining matrix had a lower density of cells. 
Increasing the concentration of cells should result in faster and more complete 
bone regeneration. 
 
The use of gene-enhanced tissue engineering overcomes the limitations 
associated with the one-time delivery of a bolus of protein by providing a 
sustained, local delivery of protein factors. We demonstrated that Shh delivery to 
bone defects, in this case through a novel gene enhanced tissue-engineering 
approach, resulted in significant bone regeneration. It is important to note that all 
three cell types, selected for use in these studies because of their reported bone 
regenerative capacity, were capable of regenerating bone but only when 
genetically enhanced with Shh. In addition, although the Shh-gene enhanced fat 
derived stem cells proved useful in bone regeneration, the unexpected cyst 
formation observed with the use of these cells may prove detrimental to long 
term bone regeneration.  Therefore, we view the Shh-gene enhanced gingival 
fibroblasts as being the best choice for future use in GETE as substantial 
amounts of new bone formation was evident throughout the matrix.   
  
In this study, a replication incompetent retroviral expression vector based on the 
LN series47 was used.  In this vector, the relatively weak rat beta-actin 
enhancer/promoter was used to drive expression of Shh.  Overexpression of 
potent morphogens under control of the stronger CMV enhancer/promoter or 
from other transient expression systems that grossly overexpress transgenes can 
be toxic.  The retroviral vectors used in this study are engineered for sustained 
local delivery of physiologic levels of the expressed gene. Other systems could 
have been used which result in local presence of supraphysiologic levels of 
protein for relatively short periods of time, but this would not mimic what occurs 
during the normal course of development during early skeletogenesis; a process 
we are trying to emulate.  Although the retroviral vector system was used in this 
study, other gene delivery systems that result in sustained presence of 
physiological levels of transgene expression can also be used in future studies.   
 In conclusion, this is the first study to demonstrate that Shh delivery to bone 
defects, in this case through a novel gene enhanced tissue-engineering 
approach, results in significant bone regeneration.  This encourages further 
development of the Shh gene enhanced tissue engineering approach for bone 
regeneration. 
MATERIALS AND METHODS 
 
Approval of Experimental Protocols 
The protocol was approved by the North Shore- Long Island Jewish Health 
System Institutional Biosafety Committee.  Animal protocols were approved by 
the North Shore- Long Island Jewish Health System Institutional Animal Care 
and Use Committee.  
 
Isolation and Culture of Primary Cell Populations 
Rabbit Periosteal-Derived Cells:  Rabbit periosteum was harvested from the 
anteromedial surface of the proximal tibia of male New Zealand White rabbits. A 
rectangular incision was made to expose the bone and periosteum was 
separated from underlying bone.  Only the cambium layer was harvested 
(confirmed by histological observation).  Harvested periosteum was diced into 1 
mm cubes and cultured in SDMEM media (composed of high glucose DMEM 
supplemented with 10 % heat inactivated fetal bovine serum, 1x 
antibiotic/antimycotic, 12 mM HEPES, 0.4 mM L-proline, and 50 mg/L ascorbic 
acid). 
Fat-Derived Stem Cells:  Fat tissue was harvested from the inguinal and 
abdominal regions of male New Zealand White rabbits. The tissue was placed in 
SDMEM and digested with 0.075 % collagenase/DNAse mixture at 37oC in a 5 % 
CO2 incubator for 1 hr.  The cell suspension was then filtered through a 100 nm 
NYTEC filter, the cells centrifuged, washed twice, and cultured in SDMEM. 
Gingival Fibroblasts:  Gingival tissue was harvested from the palate of male New 
Zealand White rabbits.  The tissue was cut into 1 mm explants and cultured in 
SDMEM at 37oC in humidified 5 % CO2.   
 
Construction of Retroviral Expression Vectors  
The Shh cDNA, isolated from human fetal lung tissue, had previously been 
cloned into the retroviral expression vector LNCX, based on the LN series of 
vectors in which the murine leukemia virus retroviral LTR drives expression of 
the neomycin resistance gene.47  In the retroviral vector plasmid pLNB-Shh, the 
Shh cDNA was cloned as a HindIII/ClaI fragment replacing the BMP-7 
HindIII/ClaI fragment in plasmid pLNB-BMP-7. The rat β-actin 
enhancer/promoter, a relatively weak housekeeping promoter with low-level 
constitutive expression, was chosen to drive expression of Shh because 
expression of potent morphogens from this promoter is not toxic to cells. The 
retroviral vector plasmids were CaPO4 transfected into GP+E 86 cells.48  
Retroviral vector particle containing conditioned media was collected 48 hr 
post-transfection and used to transduce PA317 cells in the presence of 8 µg/ml 
polybrene.49  PA317 cells were selected for 10-12 days in D10 medium 
supplemented with 300µg/ml active neomycin analog G418. Amphotropic 
retroviral vector particles were collected from a cloned producer cell line having 
a titer of ~1x106 Neo CFU/ml. 
 
Transduction and Selection of Cells  
Cells were transduced at ~25 % confluence in 6 well dishes using 400 ul of 
retroviral vector particles and 1.6 ml D10 supplemented with 8 ug/ml polybrene. 
Two separate transductions were performed overnight on consecutive nights.  
Kill control experiments determined that the 10 day selective conditions for rabbit 
MSC, FSC, and GF are 600, 1800, and 900 ug/ml active G418, respectively. 
Populations of resultant G418 selected rabbit cells were used in all studies.  
 
RT-PCR Analysis of Shh Expression 
Total RNA was isolated from ~1 x 106 transduced cells using the RNeasy kit 
(Qiagen).  First strand synthesis was performed using the Reverse Transcription 
System (Promega).  Shh RT-PCR was performed using Herculase Hot Start 
Enhanced DNA Polymerase (Stratagene) at an annealing temperature of 68oC.  
Oligonucleotide PCR primers NS186 5’ gctctacagcgacttcctcactttcctggaccg 3’ 
(forward primer in coding sequence of Shh) and NS239 5’ 
ccctttttctggagactaaataaaatc 3’ (reverse primer downstream of the Shh gene in 
the viral vector) were used to amplify a 735 bp fragment encompassing the 3’ 
end of Shh and flanking vector sequence encoded specifically by LNB-Shh.  
Other controls included plasmid pLNB-Shh template as a positive control and a 
no template control.  GAPDH primers NS159 (5’ ggtcatccctgagctgaacg 3’) and 
NS160 (5’ ttcgttgtcataccaggaaat 3’) at an annealing temperature of 54oC were 
used as control of RNA quality. 
 
Enzyme-Linked ImmunoSorbent Assay of Shh Secretion By Transduced Cells 
Cells were grown to confluence in SDMEM supplemented with G418 at a 
concentration of 1-4 x106 total cells. A 48-72-hour conditioned, low serum media 
(Optimem; Gibco) was harvested from the three cell lines (gingival fibroblasts, 
periosteal  and fat-derived stem cells) carrying the LNCX or LNB-Shh constructs. 
Indirect enzyme-linked immunosorbent assays (ELISAs) were performed by 
adding 100ul of conditioned media into 96-well flat-bottom Maxisorp plates 
(Nunc, Roskilido, Denmark). All assays were performed in triplicate. Antigen was 
bound at 37oC for 1 hour, blocked with 200ul PBS-T (Phosphate Buffered Saline 
with 0.1% Tween-20) for 1 hour at room temperature, and then washed three 
times with PBS-T. The primary antibody, goat IgGanti-mouse Shh amino-terminal 
peptide (100ug/ml; R&D Systems; Minneapolis,  MN), was diluted 1:100 in PBS-
T, and 100ul was added per well for 2 hours at room temperature. Three washes 
with PBS-T, were followed by development using a biotinylated secondary 
antibody (mouse anti-goat IgG  biotinylated antibody; Vectastain ABC kit, Vector 
Laboratories; Burlingame, CA) and horseradish peroxidase conjugate (Vectastain 
ABC kit). The chromogenic substrate tetramethylbenzidine (TMB Microwell 
Peroxidase Substrate; KPL, Gaithersberg, MD) was used for color development. 
The plates were read at OD450 using a model 400 ATC ELISA plate reader (SLT 
Lab Instruments; Grodig, Austria). Unconditioned Optimem was used as 
background control. 
 
Assembly of Gene-Modified Cell–Alginate-Collagen Matrix Constructs 
A solution of purified Type 1 bovine collagen (Vitrogen 100, 3.1mg/ml collagen; 
Cohesion, Palo Alto, CA) was prepared by adding 800 ul of Vitrogen 100 to 100 
ul of 10x PBS, followed by the addition of 100 ul of 0.1m NaOH. 
The gene-modified cell lines were trypsinized and the cell pellets were 
resuspended in a 50ml Falcon tube (Becton Dickinson; Lincoln Park, NJ) in 200ul 
of 2.0% alginic acid (sodium salt, medium viscosity, from Macrocystis pyrifera; 
Sigma, St. Louis, MO). The cell-alginate solution was added to 200 ul of the 
above prepared Type 1 collagen preparation. Initial gelation was accomplished 
by placing the cell-alginate-collagen amalgam at 37oC for 30 minutes. Gelation of 
the alginate was completed by adding 4ml of 100mM CaCl2 directly to the 
amalgam. The matrix was allowed to gel for 15 minutes and then rinsed 3 times 
with PBS prior to implantation. 
 
Surgical Procedures  
A total of 24 adult male (age 6 months) New Zealand White rabbits, weighing 3.0 
to 4.0 kg, were used in this study. The rabbits were kept in standard laboratory 
double cages with a 12-hour day/night cycle and an ambient temperature of 
21oC.  The rabbits were permitted two hours free housing per day, and had 
access to tap water and food pellets.  
Food and water were withheld from the rabbits for 6 hours and 1 hour 
respectively prior to surgery. A total of 0.4cc/3 kg of Tazidine was administered 
18 hours prior to surgery by means of intramuscular injection, Animals were pre-
anaesthetised with an intramuscular injection of 5mg/kg acepromazine, and 
induced with 12.5mg/kg ketamine and 4% Isoflurane. Adequateness of 
anaesthesia was assessed by the absence of withdrawal reflex to toe pinch and 
the absence of corneal reflex. 
In each animal, the surgical field was shaved and prepped with iodophor. 
Following the infiltration of local anaesthesia (2% lidocaine with 1:100,000 
epinephrine), midline sagittal incisions were extended from the occipital region to 
the bridge of the nose. Subperiosteal dissections were performed anteriorly and 
posteriorly to expose the frontal and parietal regions of the cranium. Using a 
trephine bur with copious saline irrigation, four full thickness 8mm bone defects 
were created. Great care was taken to avoid perforating the underlying dura. 
The surgically created defects were restored with the selected transduced cells in 
the alginate matrix or the corresponding controls. The scalp tissues were 
reapproximated to the remaining calvarium, and sutured with 4-0 Vicryl sutures. 
Post-operative analgesia was accomplished by administering 0.1 mg/kg 
Buprenex subcutaneously q12h for the first 48 hours. 
After 6 or 12 weeks, the animals were anesthetized with ketamine and sacrificed 
by means of a pentobarbital overdose. 
 
Experimental Groups 
The experimental groups comprised allogenic gingival fibroblasts, periosteal and 
fat-derived stem cells transduced with the replication incompetent Shh retroviral 
vector (LNB-Shh) and control vector (LNCX). Additional controls included 
alginate/collagen matrix alone and empty defects , for a total of 8 groups. Twelve 
calvarial defects (6 per time/group) were analyzed for each experimental group. 
 
Radiographic Analysis of Bone Defect Healing 
Post mortem radiographs (Kodak Ultraspeed DF-50 Dental Film) were taken of 
the sectioned calvaria using a portable x-ray unit (Philips Dens-o-Matic, 65 kVp, 
7.5 mAmp, 1.5 seconds).  
 
Histological Analysis 
The defect sites were identified visually, and then sectioned into halves. One half 
was decalcified in “overnight bone decalcification” solution (Decal Corporation, 
Tallman NY) for 3 days. After embedding in paraffin, 4um serial sections were 
obtained, and stained with hematoxylin and eosin.  
When processing the alginate/collagen/cell matrices for histologic examination, 
10 mM CaCl2 was added to the formalin during the initial fixation period to 
prevent depolymerization of the alginate matrix. The matrices were then fixed 
overnight with 50 mm BaCl2 at 40C to permanently cross-link the alginate prior to 
final processing. 
Quantitative digital analysis of histological sections was performed. Digitized 
composite photomicrographs were analyzed on an IBM PC running Windows 98 
with Adobe Photoshop 6.0. The mineralized area of the defects in the digitized 
radiographs was identified by the value of the pixel in the image. The percentage 
of area of mineralized tissue within the defect size was determined. 
 Statistical Analysis 
Determination of n (the minimum sample size to provide proper discriminatory 
capability) for in vivo animal studies was done by power analysis.  A sample size 
of 6 would yield 80% power to detect a difference of 10% between the two 
groups (case vs. control) using a 2-tailed, paired t-test with a 0.05 significance 
level. One-way Analysis of Variance was followed by Bonferroni pairwise multiple 
comparison.  A “p” value of less than 0.05 was considered statistically significant.   
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TABLE 1:  Oligonucleotide primers used to generate complete Shh cDNA  
 
 
 
 
 
 
 
 
 
 
 
NS145 F 5’ aaaaagcttgggcgagatgctgctgctggcgagatgtct 3’       404 bp 
NS182 R 5’ tcgtcccagccctcggtcacccgc 3’ 
 
NS181 F 5’ gcgggtgaccgagggctgggacga 3’         359 bp 
NS115 R 5’ aggaaagtgaggaagtcg 3’ 
 
NS198 F 5’ accgcgtgctggcggcggacgaccaggg 3’        520 bp 
NS199 R 5’ tgtgcgcgcgggcgccagtgcagccaggagcgcg 3’ 
 
NS189 F 5’cccgcgcgcacAgaTAgAggAggAgaTagTggTggAggTgaTAgAggAggTggTggAggAagagtagccctaaccgctccaggtgctgccg 3’
NS190 R 5’ cggcagcacctggagcggttagggctactctTccTccAccAccTccTcTAtcAccTccAccActAtcTccTccTcTAtcTgtgcgcgcggg 3’ 
 
NS200 F 5’ ctccaggtgctgccgacgctccgggtgcgg 3’        148 bp 
NS146 R 5’ tttatcgattcagctggacttgaccgccatgcccagcgg 3’ 
 
Silent mutations (capital letters) were created in the Shh coding sequence of primers NS189 and NS190, which were annealed 
together to generate a 91 bp fragment.  The mutations were needed to reduce the GC content of this region of Shh, which was 
unstable in the constructs.  All other primers were used in RT-PCR to generate the PCR fragment lengths indicated. 
  
Figure 1.  Retroviral Expression Vectors Used.  LTR: long terminal repeat, 
Neor: neomycin resistance gene; ß- act: rat beta- actin promoter; Shh: Sonic 
hedgehog gene.  Constructs are based on the LN series containing the 
selectable neomycin resistance gene driven by the 5’ LTR.  These retroviral 
vectors are generated as amphotropic retroviral vector particles from PA317 
cells. Sizes of genomic length RNA and mRNA are indicated. 
 
 
 
Figure 2.  Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) 
Analysis of Total RNA Isolated from Periosteal-Derived Cells.  Lanes: (M) 
molecular weight markers, (1) LNCX transduced, (2) LNB-Shh transduced, (3) 
No template, and (4) plasmid pLNB-Shh.  (A) RT-PCR analysis of RNA from 
periosteal-derived cells. PCR primers that amplify only vector-specific RNA 
transcripts were used to generate a 735 bp vector specific Shh PCR product. 
Note that only LNB-Shh (lane 2) and the positive control plasmid LNB-Shh (lane 
4) generate the PCR product.  (B) GAPDH control. GAPDH PCR primers were 
used to generate a 294 bp GAPDH PCR product as control for RNA integrity and 
reverse transcription reaction. 
 
Figure 3: Shh Protein Production In Transduced Cells.  
Shh protein production in the 3 cell types was assessed by Enzyme-Linked 
ImmunoSorbent Assay (ELISA) as described in the Materials and Methods. Shh 
production of LNCX control transduced cells (blue) is compared to the Shh-
enhanced cells (red). 
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Figure 4.  Histology of Alginate/Type I Collagen/ Periosteal-Derived Cell 
Composite Bone Graft Material.  (A) Alginate/type I collagen / periosteal-
derived cell composite graft with 2 x 106 cells/450 ul matrix construct, Time 0.  
(B) Similar graft after 7 days culture in vitro.  Hematoxylin and eosin stain.  
Original magnification 100x (inset 200x). 
 
 
Figure 5:  Radiographic Analysis Of Calvarial Bone Regeneration At 6 
Weeks. Significantly more bone regeneration is evident in the SHH-enhanced 
gingival fibroblasts (upper right) compared to the 3 controls. 
 
 
 
Figure 6:  Histologic Assessment of Bone Regeneration at 6 Weeks.  
(A) Unrestored empty defect. Only a thin band of fibrous connective tissue is 
present in the defect space. (B) Matrix alone. The matrix has preserved the 
thickness of the defect space. New bone formation is minimal. (C) Matrix plus 
Shh gene-enhanced periosteal-derived cells. Thin trabeculae of new bone are 
identified primarily at the surgical margins. (D) Matrix plus Shh gene-enhanced 
fat-derived stem cells. Relatively thick trabeculae of new bone are present, but 
this new bone is not evenly distributed throughout the defect site. (E) Matrix plus 
Shh gene-enhanced gingival fibroblasts. A significant amount of new bone is 
present throughout the defect space. Hematoxylin and eosin stain. Original 
magnification 4x. 
 
 
Figure 7:  Histologic Assessment of Bone Regeneration in Shh gene-
enhanced gingival fibroblasts at 6 Weeks. Significant new bone formation is 
evident. The amorphous, purple material represents remaining matrix. 
Hematoxylin and eosin stain. Original magnification 40x. 
 
 
Figure 8:  Histologic Assessment of Bone Regeneration at 12 Weeks. (A) 
Unrestored empty defect. (B) Matrix alone. (C) Matrix plus Shh gene-enhanced 
periosteal-derived cells.  (D) Matrix plus Shh gene-enhanced fat-derived stem 
cells. (E) Matrix plus Shh gene-enhanced gingival fibroblasts. Similar to the 
findings noted at 6 weeks, the Shh-gene-enhanced cells resulted in the best 
overall bone regeneration. Hematoxylin and eosin stain. Original magnification 
4x. 
 
 
 
Figure 9: Histologic Comparison of Bone Regeneration Between Groups at 
12 Weeks. (A) Unrestored empty defect control shows thin band of fibrous 
connective tissue. (B) In the matrix-only control, remaining matrix is identified. 
(C) Matrix and control transduced gingival fibroblasts. (D) Shh-gene-enhanced 
gingival fibroblasts. Compared to the three controls, significant new bone 
formation is observed. Hematoxylin and eosin stain. Original magnification 40x. 
 
 
 
 
Figure 10:  Histologic Assessment of Bone Regeneration in Shh gene-
enhanced gingival fibroblasts at 12 Weeks.  Bone formation is seen in direct 
continuity with the matrix. Bone marrow is also identified. Hematoxylin and eosin 
stain. Original magnification 40x. 
 Figure 11: Bone Rgeneration in Calvarial Defects After 6and 12 Weeks. 
Histologic slides were digitized and the total 2-dimensional amount of new bone 
in defects was quantitated using Adobe Photoshop. Data was analyzed using 
One-Way Analysis of Variance (ANOVA) followed by Bonferroni pairwise multiple 
comparison. In all cases, Shh gene enhancement of cells resulted in statistically 
significant differences (p<0.05) compared to controls. 
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